Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer: a narrative review.

Leung, Tiffany H; Ho, James C; Wang, Xiaofei; Pang, Herbert

Leung, Tiffany H; Ho, James C; Wang, Xiaofei; Pang, Herbert.

Afiliação

Leung TH; Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Ho JC; Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Wang X; Department of Biostatistics and Bioinformatics, School of Medicine, Duke University, Durham, NC, USA.
Pang H; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Chin Clin Oncol ; 12(5): 53, 2023 Oct.

Article em En | MEDLINE | ID: mdl-37817506

Assuntos

Carcinoma Hepatocelular; Neoplasias Hepáticas; Humanos; Carcinoma Hepatocelular/terapia; Taxa de Sobrevida; Neoplasias Hepáticas/terapia; Imunoterapia/métodos; Intervalo Livre de Doença

Palavras-chave

Immunotherapy; liver cancer; progression-free survival (PFS); restricted mean survival time (RMST); surrogate endpoint

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Chin Clin Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google